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Abstract
Background: Nitroxoline, a hydroxychinoline derivate, has been used for many years to treat urinary tract infections
(UTI). Many uncontrolled, but only few controlled clinical studies have been published. Four so far unpublished,
controlled clinical studies were meta-analysed.
Methods: A narrative literature review was performed. In addition the individual patient data (IPD) of 466 females
with uncomplicated UTI of four prospective, single blind, randomized, clinical studies with similar protocols using
nitroxoline (250 mg tid) versus cotrimoxazole (960 mg bid) or norfloxacin (400 mg bid) as controls for 5 days
(sporadic UTI) or 10 days (recurrent UTI) were meta-analysed. The primary aim was eradication of bacteriuria 7–13
days after end of therapy (test of cure). Clinical efficacy was determined by elimination of symptoms and safety by
adverse events and laboratory tests.
Results: Reviewing a total of 26 uncontrolled, 2 controlled and one postmarketing studies including more than
11,000 patients, good efficacy and safety of nitroxoline could be confirmed. In the four unpublished controlled
studies a total of 234 patients were treated orally with nitroxoline and 232 with controls. The safety of nitroxoline
was very good and comparable to the controls (adverse events 9.4% vs 7.8%; p = 0.360). In the mMITT set (at least
one outcome result), in the PP set (test of cure outcome) and in the modified PP set (missing test of cure rated
failure) more than 90% of the patients showed eradication of bacteriuria with nitroxoline, which also met statistical
non-inferiority compared to the controls (10% non-inferiority margin) in all three evaluation sets. The clinical efficacy
was similar between the two treatment groups.
Conclusion: The IPD meta-analysis using objective parameters (elimination of bacteriuria) demonstrated equivalent
efficacy (non-inferiority) of nitroxoline with the controls tested (cotrimoxazole, norfloxacin) in the treatment of
uncomplicated UTI. Considering the good safety and efficacy of nitroxoline as also shown in many uncontrolled
and observational studies and the world wide increase of resistance of uropathogens against cotrimoxazole and
fluoroquinolones, but not against nitroxoline within the last 20 years, nitroxoline should be reconsidered as one
of the first line antibiotics for the treatment of uncomplicated UTI.
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Background
Urinary tract infections (UTI) are very frequently found
in humans. The most frequent pathogens are Escherichia
coli and other species of Enterobacteriaceae. Gram-positive
bacteria, such as staphylococci and enterococci, and non-
fermenting Gram-negative bacteria, such as Pseudomonas
aeruginosa, can also be found [1-4]. Funguria due to
Candida spp. is mainly cultured in patients with risk
factors, e.g. immunocompromised or with infections
due to foreign bodies [5,6]. The worldwide increasing
bacterial resistance has become a general therapeutic
problem. In many countries the resistance rates of E. coli
against trimethoprim and cotrimoxazole, have exceeded
the 20% threshold accepted for empiric therapy by far
[1,3,7-9]. Although in many countries still below 20%, the
resistance rates of E. coli against fluoroquinolones are also
increasing worldwide. Therefore, cotrimoxazole, trimetho-
prim, fluoroquinolones, the former standard therapeutics
for uncomplicated UTI [10], but also amoxicillin with and
without clavulanic acid and oral cephalosporins are no
more recommended in many of the current guidelines as
first line antibiotics for the treatment of uncomplicated
UTI (cystitis) [11-13]. Older oral antibiotics, such as fosfo-
mycin trometamol, pivmecillinam, and nitrofurantoin,
which have still preserved their antibacterial activity
against E. coli and other uropathogens, are now mostly
recommended as first line antibiotics for this indication
[11-13]. But further alternatives should be looked for.
Nitroxoline, 5-nitro-8-hydroxyquinoline, has been de-
scribed first in the fifties of the last century [14]. Since
the sixties it has been used for treatment and prophylaxis
of acute and recurrent UTI [15,16] in adults and children
in the European countries. Nitroxoline is active against
most Gram-negative and –positive uropathogenic bacteria
[17-19], against mycoplasmas (M. hominis, Ureaplasma
urealyticum) [20,21] and human pathogenic Candida spp
[22,23]. The antibacterial activity against Acinetobacter
spp., Enterococcus spp., and Serratia spp. is variable and
Pseudomonas spp. are considered resistant [17,19]. Oral
treatment with nitroxoline has no qualitative and quanti-
tative effect on the fecal flora [24].
The rate of susceptibility of E. coli, the leading uro-
pathogen, at a MIC of nitroxoline of ≤8 mg/l is practically
100% and has not changed over the years as shown by
a recent in vitro study with 499 strains from patients
with community acquired UTI showing MIC50- and
MIC90-values of 2 mg/l and 4 mg/l, respectively. The
unimodal MIC distribution indicates that these patho-
gens are wild types without any acquired resistance
[25]. For other uropathogens, such as K. pneumonia, P.
mirabilis. P. vulgaris, M. morganii, and S. saprophyti-
cus the MIC50- and MIC90-values were between 4–8/
4–8 mg/l with highest MIC of 8 mg/l [26]. The MIC90
for various Candida spp., such as Candida albicans,
Candida tropicalis, Candida parapsilosis, Candida
krusei, Torulopsis (Candida) glabrata, is between 1 and
4 mg/l nitroxoline [27], which correlate well with other
studies [28].
The mode of antibacterial and antifungal action is
based on the ability of nitroxoline to chelate with various
metallic bivalent cations [29-31]. The antibacterial actvity
of nitroxoline is decreased by the presence of Mn++ and
Mg++, but not Ca++ and univalent ions like Na+ and K+.
The authors assume that magnesium ions stabilizing the
lipopolysaccharide (LPS) molecules in the outer bacterial
membrane favour the accumulation of nitroxoline in the
bacteria, such as E. coli. This process is energy independ-
ent. Nitroxoline is binding to bacterial surface structures,
which probably leads to an interaction between nitroxo-
line and magnesium ions complexing with LPS phosphate
groups [30,31]. The bacterial surface becomes hydropho-
bic as demonstrated for E. coli at 1/8 of MIC of nitroxo-
line and the adherence to catheter surface is decreased
[32]. Nitroxoline inhibits rapidly and selectively RNA
synthesis in fission yeast by chelation of bivalent cations
required for RNA synthesis [33]. Furthermore, subinhibi-
tory concentrations of nitroxoline have a major inhibitory
effect on adhesin expression and bacterial attachment
[34-36], which may add an important antibacterial mech-
anism of nitroxoline. Nitroxoline also reduces the forma-
tion and induces the dispersal of Pseudomonas aeruginosa
biofilms by chelation of iron and zinc [37].
After single oral administration of 200 mg nitroxoline
antibacterial urinary activity can be demonstrated by micro-
biological assays peaking on average between 216 mg/l and
220 mg/l during the urine collection periods 1–2 hours and
3–4 hours [38]. The HPLC concentrations of free nitroxo-
line, however, were much lower peaking on average be-
tween 3.2 mg/l and 5.8 mg/l during that periods. The
discrepancy between the two assays was explained by
antibacterial active metabolites in urine, because nitroxo-
line is excreted in the urine in unconjugated as well as
conjugated (glucuronide, sulfate etc.) forms [38,39]. A
recent study showed that after oral administration of
250 mg about 99% of the excreted nitroxoline was elimi-
nated as metabolites in urine of volunteers, mainly as
sulfate and glucuronide, and only 1.0% as the parent
component [40,41]. In this study urinary inhibitory and
bactericidal concentrations were determined against
selected uropathogens, such as E. coli, K. pneumonia,
P. mirabilis, and S. saprophyticus. In connection with
additional urinary bactericidal kinetic studies it was
concluded, that nitroxoline exhibits mainly bacteriostatic
activity in urine against susceptible strains. Its antibacter-
ial activity is more pronounced in acidic than in alkaline
urine.
The aim of this article is to review systematically the
available literature on the use of nitroxoline for treatment
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and prevention of UTI and to meta-analyse four prospect-
ive, randomized, single-blind, multicenter, comparative
studies, so far unpublished, in order to improve the evi-
dence based recommendation to use nitroxoline as one of




A narrative literature search concerning efficacy and
safety of nitroxoline in the treatment of UTI was per-
formed by the manufacturing company (Rosen Pharma,
Blieskastel, Germany). A total of 26 uncontrolled studies
including 1206 patients (947 adults and 259 children)
published between 1962 and 1987, two controlled studies
including 148 patients (100 adult and 48 children) and
one postmarketing observational study [42] including
9800 patients with uncomplicated and complicated UTI
were found (Tables 1, 2, 3 and 4).
IPD Meta-analysis of four clinical studies
The individual patients’ data (IPD) of four prospective,
randomized, single-blind, multicenter, comparative studies
(data on file, Rosen Pharma GmbH), so far unpublished,
were available for this IPD meta-analysis. The four studies
were performed to renew marketing registration during
December 1992 until 1993 in 20 investigational sites. A
total of 466 female patients suffering from acute sporadic
cystitis or acute episode of recurrent cystitis was included
in the four studies (nitroxoline: n = 234; norfloxacin: n = 54;
cotrimoxazole: n = 178). For the meta-analysis the original
individual patient’s data (IPD) could be analyzed.
The studies were performed in accordance with the
declaration of Helsinki updated in Hongkong 1989 [69].
Before start they were voted positively by the Ethical
Commissions of the Medical Councils of Saarland for
study NWNF #10 (dated 7 Sept 1992), Bavaria for study
NWNF #11 (dated 20 October 1992, Nr. 92247),
Rheinland-Pfalz for study NWNF #13 (dated 3 November
1992), and Hessen for study NWNF # 15 (dated 2 November
1992, Nr. 71/92), and the respective countries of Germany
where the studies where performed. A registration in a
public trials registry was not required at that time.
Study design
The four clinical studies were prospective, randomized,
single-blind (patient blinded), multicenter, and com-
parative in parallel groups. The aim of the studies was
to compare the efficacy and safety of nitroxoline versus
cotrimoxazole and norfloxacin in female patients with
acute uncomplicated sporadic cystitis (NWNF 10, 11,
13) or with acute episode of recurrent uncomplicated
cystitis (NWNF 15). In Table 5 the main parameters of
the design of the four studies are outlined.
Selection of patients
After medical history including kind and duration of
symptoms, pretreatment and concurrent medication,
physical examination including body temperature, urin-
alysis and confirmation of the clinical diagnosis including
additional tests needed, eligible patients were informed
about aim, performance, possible adverse events and their
right to terminate the study without giving any reasons. If
written informed consent was documented, patients were
included into the study after inclusion and exclusion cri-
teria had been checked.
In three studies (NWNF 10, 11, 13) female patients
with clinical signs and symptoms of acute sporadic un-
complicated cystitis and in one study (NWNF 15) those
with acute episode of recurrent uncomplicated cystitis
were included. In all patients a pretreatment midstream
or single catheter urine sample was requested to show
pyuria (white blood cells >5 000/ml) and bacteriuria with
colony forming units (CFU) ≥ 105/ml due to susceptible
pathogens.
According to the study protocol exclusion criteria
were: age below 18 years; taking part in a clinical study
during the last 30 days; pregnancy; urolithiasis or ob-
struction within the urinary tract; severe systemic,
gastrointestinal, kidney or liver diseases; hypertension;
diabetes mellitus; known erythema exsudativum multi-
forma, pathologic hemogram including hemoglobin anom-
alies; glucose-6-phosphate-deficiency; acute porphyria;
folic acid deficiency; known seizure disorder; and allergy
against sulfonyl urea antidiabetics and sulfonamide based
diuretics.
Randomization, treatment, and visits
Female patients were randomized in two age groups
(upto 45 and above 45 years) and received their allocated
antibiotic wrapped in a neutral box signed “for clinical
study only”. Because an objective outcome (eradication
of bacteriuria) was the primary aim of the study, a
double-blind design was not considered necessary at
that time.
Table 1 Total number (n) of published clinical studies on
treatment of urogenital infections with nitroxoline as
found by the narrative literature search
Study design Population Studies (n) Patients (n)
Uncontrolled Adults 15 947
Uncontrolled Children 11 259
Controlled vs. norfloxacin Adults 1 100
Controlled vs. TMP/SMX Children 1 48
Observational Adults 1 9,800
Total 29 11,154
TMP/SMX – trimethoprim/sulfamethoxazole.
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Patients in the nitroxoline group were asked to take
one capsule containing 250 mg nitroxoline three times
daily with the three main meals. Patients of the con-
trol group were asked to take one tablet containing
960 mg cotrimoxazole (NWNF 10, 11, 15) or 400 mg
norfloxacin (NWNF 13) twice daily with the morning
and evening meal. The treatment duration was 5 days
in 3 studies (NWNF 10, 11, 13) and 10 days in one
study (NWNF 15). The control visits were one day
(end of treatment) and 7–13 days (test of cure) after
end of therapy. In the ten day treatment study (NWNF
15) an additional visit during therapy at day 6 was
scheduled.
Primary objectives The primary objective was the
eradication (CFU <104/ml) of the bacteriuria due to sus-
ceptible pathogens at test of cure in compliant patients
(≥80% of medication) without taking any additional
antibiotic.
Secondary objectives Secondary objectives were clinical
efficacy and safety. For clinical efficacy the following
symptoms were scored (0-absent upto 5-very severe)
by the patient: dysuria, frequency, urgency, nycturia,
flank/back pain. The clinical efficacy was assessed also
globally by the patient and the investigator. At each
visit patients were asked for any adverse event, which
was documented. The safety was assessed also globally
by the patient and the investigator.
The following laboratory tests were performed: Urin-
alysis (white and red blood cells, nitrite reaction, pro-
tein, glucose, pH), serum chemistry (glucose, creatinine,
bilirubin, AST, ALT, gammaGT, sodium, potassium,
calcium) and hematology (red and white blood count,
thrombocytes, blood sedimentation rate).
Evaluation sets
The efficacy and safety was analysed in the following
patients’ sets:
Table 2 Fifteen uncontrolled clinical studies with nitroxoline in 947 adult patients of both genders
First author Year Pat (n) Indication (T/P) Dosage Duration Success rate Adverse events
Kuss [43] 1962 72 T: acute cUTI & uUTI 400 mg/d 20–45 days 78% 1.3% gastrointestinal
Moreau [44] 1962 20 T: acute cUTI 400–500 mg/d 8–10 (−45)
days
90% 5% gastrointestinal
v. Rütte [45] 1969 200 P: chronic rUTI 300–500 mg/d 2–3 months 80% 0%
shortly 800 mg/d 1 day
Uhlir [46] 1972 20 T: acute UTI (7), chronic
PN (13)
300 mg/d 14 days 100% 0%
Allal [47] 1973 264 T: UTI during pregnancy 300 mg/d 6 days > 75% No data
Bittard [48] 1974 50 P: post-op. catheter 7.5–10 mg/kg/d 6 weeks 92% Few gastrointestinal
Schlesinger [49] 1975 65 T: chronic PN (62), chronic
prostatitis (3)
300–500 mg/d 10 days 80% clinical 0%
Aubert [50] 1976 28 T: post-op. catheter, after
endoscopy
200–300 mg/d 10–15 days 72% 0%
Dufour [51] 1979 15 T: acute prostatitis 900–1600 mg/d 3–5 days 81% No data
Lenzner [52] 1983 60 T: fungal UTI 750 mg/d 10–20 days 80% 3.3% itching; few cases
with nausea and
vomiting
Schülke [53] 1984 50 T: postop., acute UTI after
removal of urethral catheter
for 3–10 days
750 mg/d 3 days 78% 0%





Demontrond [55] 1986 15 T: candiduria in hospitalised
patients
600 mg/d 10–30 days 87% 0%
Frobert [56] 1987 36 T: acute, uUTI in hospitalised
patients
600 mg/d 10 days 93% bacteriological 5.5% gastrointestinal
87% clinical 2.7% nausea
2.7% dizziness
Cancet [27] 1987 8 T: urogenital fungal infections 600 mg/d 15 days 100% no data
T-therapy; P-prophylaxis; UTI-urinary tract infection; uUTI-uncomplicated UTI; cUTI-complicated UTI; PN-pyelonephritis.
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Table 3 Eleven uncontrolled clinical studies on treatment and prophylaxis of UTI with nitroxoline in 259 children
First author Year Patients (n) Indication (T/P) Dosage Duration Success rate Adverse events
Lecornu [57] 1974 25 children T: compl. and uncompl. UTI 50–400 mg/d as suspension 4–12 days 72% 8% nausea
0–13 years
Roussel [58] 1974 24 children T: compl. and uncompl. UTI 10 mg/kg/d as suspension 10 days- 6 months 79% 0%
7 days–6 months
Raynaud [59] 1974 19 children T: compl. and uncompl. UTI 10 mg/kg/d as suspension 20 days 69% 10% nausea
0–10 years
Luckel [60] 1975 25 children P: compl. and uncompl. UTI 10–20 mg/kg/d as suspension 17–55 days 83% 0%
0–8.5 years
Viville [61] 1975 22 children P: compl. UTI 10–30 mg/kg/d as suspension 3–6 months 86% 0%
2 months-17 years
Chable [62] 1975 28 children T: compl. and uncompl. UTI 10–20 mg/kg/d as suspension 10 days 81% 0%
2 month-14.5 years
Battin [63] 1975 30 children P: compl. and uncompl. UTI 10 mg/kg/d as suspension 6 weeks 90% 0%
2 month-10 years
Sorez [64] 1975 30 children T: compl. and uncompl. UTI 10–25 mg/kg/d as suspension 10 – 17 days 73.7% uncompl. UTI 40% compl. UTI 0%
10 days-8 years
Neimann [65] 1975 21 children T/P: compl. and uncompl. UTI 25–400 mg/d as suspension 4 days-4 months 90% 10% nausea
26 days-8 years
Machecourt [66] 1976 23 children T: compl. and uncompl. UTI 10–20 mg/kg/d as suspension 10 days 91% 0%
21 days-14 years
Lambert-Zechovsky [24] 1987 12 children T: uncompl. UTI 20 mg/kg/d as suspension 10 days 66% (91% incl. non-compliance) -
aver. 4 years




















Safety set: All patients included into the study having
received any study medication.
Modified microbiologically Intention-to-Treat Set
(mMITT): All patients with significant bacteriuria
(CFU ≥105/ml) at study entry; with at least one control
visit including microbiological investigation, and with
a consistent clinical report (in study NWNF 10 few
clinical reports were inconsistent). The last observa-
tion was brought forward (LOF), if not failure has
already been documented and an additional antibiotic
been administered.
Per Protocol Set (PP): All patients with significant
bacteriuria (CFU ≥105/ml) at study entry; with test of
cure visit including microbiological investigation (except
failure was already documented and additional antibiotic
administered); doubtless randomization; and compliance
(≥80% of allocated drug).
Modified per Protocol Set (mPP): All patients with
significant bacteriuria (CFU ≥105/ml) at study entry;
with test of cure visit including microbiological investi-
gation; missing test of cure visit was rated as failure
(worst case) [70]; doubtless randomization; and compli-
ance (≥80% of allocated drug).
Statiscial analysis
The individual patient data were entered and independ-
ently checked to ensure high data quality. Categorial data
are described by absolute and relative frequencies. Ordinal
data are either described in tables by absolute and relative
frequencies (global clinical assessment) or by box plots
(scoring of clinical symptoms). For numerical data median
as well as minimum and maximum value are given.
To evaluate the noninferiority of nitroxoline compared
to the controls with regard to the failure rate the differ-
ence of the failure rates of the two treatments and its
95%-confidence interval is estimated [71]. Odds Ratios are
estimated, too. Difference as well as odds ratio are esti-
mated by logistic regression with random center effect
[72]. Since the proportion of variance explained by the
centers exceeded substantially the proportion of variance
explained by the four studies random center effects in-
stead of random study effects were added to the model.
Wether the distribution of ordinal data is the same in the
two treatment groups is analyzed by ordered probit
regression, the distribution of numerical data is compared
by linear regression. For both approaches random center
effects are taken into account.
Table 5 Study design of the four meta-analysed prospective, open, randomised clinical studies in female patients with
acute uncomplicated and recurrent cystitis treated with nitroxoline (NTX) versus a control antibiotic, cotrimoxazole
(CTX) or norfloxacin (NFX)




NWNF 10° Nitroxoline (NTX) Cotrimoxazole (CTX) Acute uncompl. cystitis 130 total 5 days day 6 day 12–14
3×250 mg 2×960 mg 67 NTX, 63 CTX
NWNF 11 Nitroxoline (NTX) Cotrimoxazole (CTX) Acute uncompl. cystitis 115 total 5 days day 6 day 12–14
3×250 mg 2×960 mg 56 NTX
59 CTX
NWNF 13 Nitroxoline (NTX) Norfloxacin (NFX) Acute uncompl. cystitis 105 total 5 days day 6 day 12–14
3×250 mg 2×400 mg 51 NTX
54 NFX
NWNF 15 Nitroxoline (NTX) Cotrimoxazole (CTX) Acute episode of uncompl.
recurrent cystitis
116 total 10 days day 11–13* day 21–23
3×250 mg 2×960 mg 60 NTX
56 CTX
°inclusion criteria missing (no urine cultures reported): total 12, NTX 7, CTX 5 patients (included in safety set only).
*additional visit during therapy: day 6–8.
Table 4 Two controlled open clinical studies in a total of 148 patients with nitroxoline (NTX) versus norfloxacin (NFX)
or cotrimoxazole (CTX); SMX-sulphamethoxazole; TMP-trimethoprim
First author Year Pat.(n) Indication (T/P) Antibiotic and dosage Duration Success rate Adverse events
Schülke [67] 1986 51 NTX T: postop., uncompl. UTI 750 mg NTX/d vs. 800 mg
NFX/d
3 days 60.8% NTX 59.2% NFX 0%
49 NFX
Dodat [68] 1988 48 children P: postop. UTI
(ureteral reflux)
10 mg NTX/kg/d 30–60 days 95% NTX 6% NTX
0–8 years vs. 15 mg SMX/ 3 mg
TMP/kg/d
95% CTX 5% CTX
T-therapy; P-prophylaxis, UTI-urinary tract infection.
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All p-values are two-sided, the level of significance is




The 26 uncontrolled clinical studies published between
1962 and 1987 included a total of 1206 patients (947
adults and 259 children) (Table 1). Nitroxoline was mainly
administered for treatment of uncomplicated and com-
plicated UTI as well as for prophylaxis of recurrent UTI
with daily dosages mostly between 300 and 900 mg. The
treatment duration varied mainly between 3 and 10 days
depending on the indication. Study details are presented
in Tables 2 and 3.
The summary results of the two controlled studies
including 148 patients (100 adult and 48 children) are
outlined in Table 4. In one study 51 patients received
250 mg nitroxoline tid versus 49 patients 400 mg norflox-
acin bid for treatment of postoperative and uncomplicated
UTI [67]. The microbiological outcome was comparable
in both groups (about 60%); no adverse events were re-
ported. The second controlled study was performed in 48
children with ureteral reflux [68]. The children received
either nitroxoline or cotrimoxazole for prophylaxis of UTI
for 30–60 days. In 95% of the children a recurrent UTI
could be prevented in both groups. Adverse reactions
were reported in 6% with nitroxoline and in 5% with
cotrimoxazole.
The postmarketing observational study included 9800
patients (75% women, 25% men) with complicated and
uncomplicated UTI including recurrent UTI, and to a
lesser extent also with fungal urogenital infections [42].
The dosage of nitroxoline was fixed at 250 mg tid, but
the treatment duration was chosen according to the
physician’s decision. The physician’s assessment revealed
clinical success of 95% in cystitis, 79% in recurrent and
complicated UTI; 80% in pyelonephritis, and 91% in fun-
gal infections. The overall patient’s assessment of success
was 95%. Only 2.2% of the patients reported adverse




The studies were performed in 20 German cites from
Dezember 1992 until 1993. A total of 466 female pa-
tients (nitroxoline: n = 234, controls: norfloxacin: n = 54;
cotrimozazole: n = 178) was included in the four clinical
studies. In the IPD meta-analysis the results obtained
from patients in the nitroxoline group were compared
with those obtained from patients in the control groups,
norfloxacin and cotrimoxazole.
Demography, history and physical examination
In Table 6 some data concerning demography, history
and physical examination are compared between nitroxo-
line and controls in the safety set. A significant difference
was only found as a slightly higher body mass index,
higher systolic blood pressure and a lower proportion pre-
treated by antibiotics in the group of the controls. Both
groups included about the same number of patients upto
45 and above 45 years. Although diabetes mellitus and
hypertension, considered as exclusion criteria in the ori-
ginal protocol, was found in some patients in both groups,
these patients were not excluded from the meta-analysis,
because these underlying diseases were considered only
minor protocol violations.
Flow of patients
In Figure 1 the total number of patients included in the
studies is shown, randomized to nitroxoline and controls
and excluded because of different reasons from the
evaluation sets. Finally the safety (mMITT/mPP/PP) set
comprised 234 (211/205/200) patients in the nitroxoline
and 232 (213/210/206) in the control groups.
Quality of the studies
Each of the four randomized clinical trials achieved a
good quality with four out of maximum five Jadad scores
[73,74]: randomization (1 score), which was appropriate
(1 score), patient blinding only (0 score), which was appro-
priate (1 score), and drop-outs well-grounded (1 score).
Bacterial spectrum and resistance to study drugs
The bacterial spectrum and resistance at study entry
(visit 1) is shown in Table 7. On average about 10% of
the patients were included with mixed infections. There-
fore the total number of isolates were higher than the
number of patients included. Escherichia coli was the
most frequent pathogen in all studies ranging from 65% to
73% of all isolates. The percentages of resistant isolated to
nitroxoline ranged from 0% to 5.5% and that to the
control antibiotics from 0.8% to 5.2%. There was no evi-
dence, that patients with recurrent UTI (study NWNF 15)
showed more resistant strains than patients with sporadic
UTI (studies NWNF 10,11,13).
Microbiological outcome
The micobiological outcome (eradication of bacteri-
uria <104/ml) as primary study aim is shown in Table 8. In
all three evaluation sets the eradication rates were above
90% in the nitroxoline and in the control groups. The 95%
confidence intervals (CI) of the estimated eradication rate dif-
ferences met statistical non-inferiority compared to the con-
trols (10% non-inferiority margin) in all three evaluation sets.
Figure 2 shows the 95% CI of the individual studies
and the total result of the four meta-analysed studies
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together in the mMITT and the PP sets with the con-
tributing weight of each study.
The eradication rates of E. coli in mono and mixed
infection and Non-E. coli mono and mixed infections in
the PP set are shown in Table 9. As expected about 80%
(79.0% vs 79.6%) of the patients in both groups had an
E. coli infection either as mono or mixed infection with
overall eradication rates of 94.3% and 96.3%, respectively.
In the about 20% Non-E. coli infections the overall eradi-
cation was 83.3% and 93.0% in the nitroxoline and the
control groups, respectively.
Clinical efficacy
In Figure 3 the clinical efficacy in the PP sets are pre-
sented as reduction of symptoms as scored pre- and post-
treatment. At the end of therapy no significant differences
were seen in dysuria (pain during micturition), nocturia
and flank/back pain between the two groups. Marked re-
ductions of frequency (pollakisuria) and urgency (impera-
tive micturition) were also seen (included) in both groups,
which were, however, more pronounced in the controls.
Considering the overall low scores achieved at the end of
therapy, the differences may not be clinical relevant.
Global clinical assessment
In the global clinical assessment (Table 10) the patient
(investigator) rated the treatment with nitroxoline in 91.2%
(90.5%) and that with the control antibiotics in 96.2%
(95.5%) as very good or good.
Safety
The treatments with nitroxoline and the control antibiotics
were generally well tolerated (Table 11). A total of 9.8%
treated with nitroxoline and 7.8% treated with a control
Figure 1 Diagram showing flow of patients participating in the
four studies on treatment with nitroxoline or with a contol
antibiotic, cotrimoxazole or norfloxacin.mMITT-modified microbio-
logical intention to treat; mPP-modified per protocol; PP-per protocol.
Table 6 Demography, history, and physical parameters of female patients investigated in the safety set
Nitroxoline Controls p-value
Demographic parameter n Median (range) n Median (range)
Age (years) 234 48 (18–89) 232 47 (18–85) 0.520
-up to 45 years 234 113 (48.3%) 232 115 (49.6%) 0.745
Height (cm) 234 165 (150–185) 231 165 (145–187) 0.290
Weight (kg) 234 62 (43–100) 232 64 (42–102) 0.125
Body mass index (kg /m2) 234 23.0 (15.9–41.3) 231 23.2 (15.6–38.0) 0.038
Heart rate (min −1) 231 80 (52–172) 231 80 (56–120) 0.354
Systolic BP (mmHg) 232 120 (80–195) 231 130 (100–190) 0.025
Diastolic BP (mmHg) 232 80 (60–120) 231 80 (50–120) 0.410
No hypertension (SBP≤ 140 mmHG) 232 165 (71.1%) 231 137 (59.3%) 0.004
Mild hypertension (SBP > 140 mmHG) 232 46 (19.8%) 231 63 (27.3%)
Moderate hypertension (SBP > 160 mmHG) 232 17 (7.3%) 231 22 (9.5%)
Severe hypertension (SBP > 180 mmHG) 232 4 (1.7%) 231 9 (3.9%)
Diabetes mellitus 234 11 (4.7%) 232 6 (2.6%) 0.230
Duration of urinary symptoms (d) 165 3 (1–30) 168 3 (1–21) 0.442
Pretreatment with antimicrobials* 234 16 (6.8%) 232 8 (3.4%) 0.060
Only unspecific pretreatment# 234 25 (10.7%) 232 28 (12.1%) 0.667
*antibiotics, chemotherapeutics.
#spasmolytics, analgetics, tea etc.
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antibiotic reported any adverse event (p = 0.360). Only 5
(nitroxoline 3; controls 2) patients discontinued the treat-
ment prematurely because of adverse events. The main
adverse events were gastrointestinal disorders (nitroxoline
19; controls 9). In 3 patients of each group allergic reac-
tions including itching, urticaria and in one case with
papules/pustules (nitroxoline) were seen.
In the laboratory parameters (Table 12) no significant
differences between critical values were observed between
the two treatment groups (nitroxoline/controls), except a
higher pretreatment (12.8% vs. 6.4%), but not posttreat-
ment rate of critical values regarding the number of blood
erythrocytes in the nitroxoline group.
Discussion
When nitroxoline was first marketed in the European
Union in 1962 for treatment and prophylaxis of UTI,
microbiological and observational studies were considered
sufficient. For this reason between 1962 and 1987 only un-
controlled studies were published not only for treatment
and prophylaxis of uncomplicated, but also for treatment
of complicated UTI including pyelonephritis, prostatitis
and fungal infections in adults of both genders, and also
in children. Only two prospective randomized studies, one
for treatment of uncomplicated UTI in adults and one for
prophylaxis of UTI in children, were published, both with
low number of patients [67,68]. Although these studies
may not be considered highly evidential, they can at least
contribute to establish the safety of nitroxoline in adults
as well as in children together with the large postmarket-
ing observational study.
When the requirements became more stringent for
the renewal of the regulatory approval, finally achieved
in Germany in 2005, four prospective randomized sin-
gle blind studies were performed during 1992 and
1993 with cotrimoxazole and norfloxacin as controls.
All four studies followed in essence the same protocol
with the only difference that the treatment duration in
women with sporadic uncomplicated UTI was five
days and in women with acute episode of recurrent
Table 8 Microbiological success (eradication of bacteriuria) in the different evaluation sets
Evaluation set Nitroxoline Controls Difference (%) (95%-CI) Odds ratio (95%-CI)
mMITT 192/211 (91.0%) 203/213 (95.3%) −3.4 (−9.7 to 3.0) 0.47 (0.21 to 1.06)
PP 184/200 (92.0%) 197/206 (95.6%) −2.2 (−8.2 to 3.7) 0.47 (0.19 to 1.14)
mPP 185/205 (90.2%) 197/210 (93.8%) −2.9 (−9.9 to 4.1) 0.60 (0.28 to 1.27)
mMITT-modified microbiological intention to treat; PP-per protocol; mPP-modified per protocol.
Difference: nitroxoline – controls.
Odds Ratio: nitroxoline vs controls.
Estimation by logistic regression with random center effect.
Table 7 Bacterial spectrum and resistance (R) against nitroxoline (Ni) versus controls (C), cotrimoxazole or norfloxacin,









R(n) NWNF 10–13 R(n) NWNF 10–15 R(n)
Bacterial
isolates
n (%) Ni/C n (%) Ni/C n (%) Ni/C n (%) Ni/C n (%) Ni/C n (%) Ni/C
E. coli 82(67.2%) -/1 88(65.3%) 1/6 81(67.0%) −/− 98(73.0%) −/− 251(66.4%) 1/7 349(68.2%) 1/7
Proteus spp.* 20(16.4%) −/− 9(6.7%) −/− 8(6.6%) −/− 12(9.0%) −/− 37(9.8%) −/− 49(9.6%) −/−
Klebsiella spp. 1(0.8%) −/− 5(3.7%) −/− 1(0.8%) −/− 6(4.5%) −/− 7(1.9%) −/− 13(2.5%) −/−
Enterobacter spp. - - 2(1.5%) −/− 3(2.5%) −/− 7(5.2%) -/2 5(1.3%) −/− 12(2.3%) -/2
Citrobacter spp. 2(1.6%) −/− - −/− 1(0.8%) −/− 1(0.8%) −/− 3(0.8%) −/− 4(0.8%) −/−
Enterococci 9(7.4%) −/− 13(9.7%) 6/1 13(10.7%) -/1 2(1.5%) −/− 35(9.3%) 6/2 37(7.2%) 6/2
Staphylococci 5(4.1%) −/− 7(5.2%) −/− 13(10.7%) 1/- 8(6.0%) −/− 25(6.6%) 1/- 33(6.4%) 1/-
Streptococci 2(1.6%) −/− 2(1.5%) −/− 1(0.8%) −/− - −/− 5(1.3%) −/− 5(1.0 %) −/−









-/2 378(100%) 8/9 512(100%) 8/11
-/0.8% 5.2/5.2% 0.8/0.8% -/1.5% 2.1/2.4% 1.6/2.1%
Isolates/patients 122/122 135/115 121/105 134/116 378/350 512/466
(1.0) (1.17) (1.15) (1.16) (1.08) (1.1)
*indol positive and negative strains.
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UTI was ten days. All four studies were of high quality
achieving four out of maximum five Jadad scores
[73,74]. The bacterial spectra were similar between the
studies with E. coli as most frequent pathogen ranging
from 65% to 73%. There was no evidence that females
suffering from recurrent UTI showed more resistant
strains than those with sporadic UTI. During the years
1992–1993, when the studies were performed, the re-
sistance rates for cotrimoxazole and norfloxacin were
still very low. Both antibiotics were considered first
Figure 2 Estimated difference (95%-confidence interval) between the microbiological success and weights from random effects analysis in
the mMITT-Set and PP-Set of patients treated with nitroxoline as compared to controls in the four studies analysed. mMITT-modified
microbiological intention to treat; PP-per protocol.
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line drugs for the treatment of uncomplicated UTI at
that time [10]. For all these reasons, including the data
of all four studies in one meta-analysis was justified.
Since the clinical report forms (CRF) of the individual
patients were available, an IPD meta-analysis could be
performed, a specific type of systematic review [75].
Rather than extracting summary (aggregate) data from
study publications, the original research data are
sought directly for each study. These data can then be
re-analysed centrally and combined, if appropriate, in
meta-analyses. IPD meta-analyses can improve the quality
of data and their analysis and thus produce more reliable
results [76]. For this reason they are considered a ‘gold
standard’ of systematic review in contrast to meta-analyses
of aggregate data, which relates to information averaged or
estimated across all individuals in a study. In a two step
approach the individual participant data are first analysed
in each separate study independently and then synthesized
using a suitable model for meta-analysis of aggregate data.
With individual participant data an analytic standardisation
across the studies and a direct derivation of the information
requested is possible, independent of significance or how it
was reported.
Since at that time the microbiological evaluation was
the primary aim practically in all UTI studies, a single-
blind design was considered sufficient, because the
eradication (primary aim) could be determined in an ob-
jective manner. Nevertheless, from todays point of view
the single-blind design could be considered as a weak-
ness of the studies, which may have affected mainly the
clinical outcome and some subjective adverse events.
However, the non-inferiority of nitroxoline for the eradica-
tion of bacteriuria as compared to the controls, cotrimox-
azole and norfloxacin, is fairly well established by this IPD
meta-analysis, whereas the individual studies contributed
each between about 20 and 30% to the final results. An-
other shortcoming of the study may be, that after the test
of cure the patients were not followed for a longer time.
Therefore no information is available concerning the re-
lapse rate after the test of cure visit.
Since the final microbiological evaluation in UTI
studies is usually not performed at the end of treatment,
but rather after the antibiotic substances are completely
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Figure 3 Clinical efficacy (symptom scoring) in the PP treated
by nitroxoline (n=193) and the controls (n= 203) (no assessment
in 10 patients).
Table 9 Microbiological success (eradication of bacteriuria)
according to bacterial groups in the PP set
Nitroxoline Controls
Monoinfection E. coli 129/138 (93.5%) 141/145 (97.2%)
Mixed infection E. coli 20/20 (100%) 17/19 (89.5%)
Monoinfection with Non-E. coli 28/34 (82.4%) 37/40 (92.5%)
Mixed infection with Non-E. coli 7/8 (87.5%) 2/2 (100%)
Total 184/200 (92.0%) 197/206 (95.6%)
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eliminated from the urinary tract and uropathogens, still
present, have had time to multiply to significant numbers,
the usual ITT and PP analyses may benefit good results,
when patients drop out with favourable results after the
end of treatment visit. These patients are considered a
microbiological cure in the ITT set (last observation
brought forward) and are drop outs for the classical PP
analysis. Thus, possible treatment failures will be not
recorded, because usually the reasons for dropping out
after the treatment visit remains unknown. Therefore,
Table 11 Adverse events
Adverse events (AE) Nitroxoline Controls
Patients (total) 234 (100%) 232 (100%)
Patients with AEs# 23 (9.8%) 18 (7.8%)
Adverse events (total) 33 26
Nervous system disorders Headache 3 4
Dizziness - 3
Eye disorders Eyelid swelling 1 -
Cardiac and circulation disorders Circulation disorder - 1






Metabolim and nutrition disorder Anorexia 1 -
Urinary disorders Incontinence 1 -
Reproductive system disorders Colpitis 1 1
Fluor vaginalis 1 -
Tubal tumor - 1
Immune system disorders Allergy 1* 1
Skin and subcutaneous tissue disorders Itching 1 1
Urticaria 1 1
Herpes labialis - 1
General disorders Intolerance 1 -
Weakness 1 -
Fever 1 -
Musculoskeletal, connective tissue and bone disorders Back pain - 1
Flank pain - 2
Leg pain - 1
#comparison of nitroxoline vs. controls (logistic regression with random center effect) p = 0.360; *with papules/pustules.
Table 10 Global clinical assessment by the investigator in the PP set (no assessment in 103 patients)
Assessment Investigator Patient
Group Nitroxoline (n = 148) Controls (n = 158) Nitroxoline (n = 148) Controls (n = 158)
Very good 115 (77.7%) 138 (87.3%) 109 (73.6%) 123 (77.8%)
Good 19 (12.8%) 13 (8.2%) 26 (17.6%) 29 (18.4%)
Satisfactory 4 (2.7%) 5 (3.2%) 5 (3.4%) 4 (2.5%)
Moderate 1 (0.7%) 0 (0%) 3 (2.0%) 1 (0.6%)
Insufficient 9 (6.1%) 2 (1.3%) 5 (3.4%) 1 (0.6%)
p-value* 0.006 0.143
*comparison of nitroxoline vs. controls (ordered probit regression with random center effect).
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a modified PP set was evaluated, in which all patients
dropping out before test of cure were considered treat-
ment failure (worst case scenario). Only if the same
results can be achieved in all three evaluation sets, the
overall result (non-inferiority) can be taken as proven,
which was established by this IPD meta-analysis for
nitroxoline as compared to the controls.
The current guidelines do usually not recommend a
longer treatment duration of an acute episode in women
with recurrent UTI than in those with sporadic UTI any
more. For cotrimoxazole and fluoroquinolones even a
3-day therapy is considered sufficient in acute uncom-
plicated cystitis, but for the usage of macrocrystal nitro-
furantoin also a 5-day therapy is recommended in the
current guidelines [11-13]. Therefore a 5-day therapy of
nitroxoline 250 mg tid should also be recommended as
one of the first line options for the treatment of acute
uncomplicated UTI (cystitis). Since about half of the
female patients were pre- and postmenopausal in the
studies meta-analysed, the dosage regimen and duration
for both female groups can be considered the same, be-
cause in current guidelines an acute cystitis in otherwise
healthy postmenopausal women is also considered as
uncomplicated [12].
Conclusions
Nitroxoline used for more than 50 years for the treatment
and prophylaxis of adult patients and children suffering
from UTI has shown good clinical efficacy and safety as
published in 26 uncontrolled, in two earlier controlled
and in one large postmarketing observational study in-
cluding a total of more than 11,000 patients. This first
IPD meta-analysis of four so far unpublished, prospective,
randomized, comparative clinical studies with a total of
466 female patients with sporadic or recurrent uncom-
plicated UTI has demonstrated non-inferiority (10%
non-inferiority margin) between treatment with nitroxo-
line versus controls (cotrimoxazole, norfloxacin). With a
5-day (sporadic UTI) and 10-day (recurrent UTI) treatment
with nitroxoline 250 mg t.i.d. eradication of bacteriuria
could be achieved in over 90% of the patients. The safety of
nitroxoline was comparable with that of the controls. Ad-
verse events, mainly gastrointestinal disorders and only a
few allergic reactions, were reported only in 9.4% patients
Table 12 Laboratory parameters before and after treatment in the safety-set
Critical values Pretreatment Posttreatment
Nitroxoline Contols p-value* Nitroxoline Contols p-value*
Glucose (mg/dl) < 55, >160 20/227 (8.8%) 12/226 (5.3%) 0.138 12/206 (5.8%) 7/207 (3.4%) 0.242
Creatinine (mg/dl) > 1.8 1/228 (0.4%) 1/227 (0.4%) 0.998 1/205 (0.5%) 0/207 (0%) -
Bilirubin (mg/dl) < 0.1, >2.0 3/226 (1.3%) 1/227 (0.4%) 0.337 2/205 (1.0%) 4/207 (1.9%) 0.426
SGOT –AST (U/l) < 35, > = 150 224/226 (99.1%) 225/226 (99.6%) 0.570 203/205 (99.0%) 206/207 (99.5%) 0.564
SGPT - ALT (U/l) < 35, > = 150 222/226 (98.2%) 225/226 (99.6%) 0.212 204/205 (99.5%) 207/207 (100%) -
gamma-GT (U/l) < 3, >38 9/227 (4.0%) 10/226 (4.4%) 0.807 9/205 (4.4%) 6/207 (2.9%) 0.412
Sodium (mmol/l) < 130, >150 8/228 (3.5%) 6/226 (2.7%) 0.603 11/205 (5.4%) 5/207 (2.4%) 0.132
Potassium (mmol/l) < 3.6, >6.0 22/228 (9.6%) 19/226 (8.4%) 0.628 19/205 (9.3%) 12/206 (5.8%) 0.229
Calcium (mmol/l) < 8, >11.5 229/229 (100%) 227/227 (100%) - 206/206 (100%) 206/206 (100%) -
Hemoglobin (g/dl) < 10, >17 0/227 (0%) 0/219 (0%) - 1/201 (0.5%) 2/204 (1.0%) 0.582
Hematocrit (%) < 32, >47 25/227 (11.0%) 33/220 (15.0%) 0.197 20/201 (10.0%) 33/204 (16.2%) 0.065
Erythrocytes (Mio/μl) < 4, >5.1 29/227 (12.8%) 14/220 (6.4%) 0.024 22/201 (10.9%) 26/205 (12.7%) 0.588
Leucocytes (Tsd/μl) < 4, >11.3 25/227 (11.0%) 21/220 (9.5%) 0.605 13/200 (6.5%) 16/204 (7.8%) 0.614
Neutrophiles (%) < 39, >75 22/225 (9.8%) 37/221 (16.7%) 0.031 15/199 (7.5%) 13/203 (6.4%) 0.656
Eosinophiles (%) < 1, >10 10/223 (4.5%) 19/219 (8.7%) 0.080 11/199 (5.5%) 8/203 (3.9%) 0.399
Basophiles (%) 0, >15 38/222 (17.1%) 47/220 (21.4%) 0.257 29/199 (14.6%) 38/203 (18.7%) 0.266
Lymphocytes (%) < 10, >50 9/221 (4.1%) 12/220 (5.5%) 0.391 7/198 (3.5%) 11/203 (5.4%) 0.382
Monocytes (%) < 3, >25 7/223 (3.1%) 14/220 (6.4%) 0.117 9/199 (4.5%) 6/203 (3.0%) 0.410
Retikulocytes (%) < 0.5, >2 220/224 (98.2%) 212/218 (97.2%) 0.493 198/200 (99.0%) 200/205 (97.6%) 0.227
Thrombocytes (Tsd/μl) < 150, >450 11/225 (4.9%) 8/218 (3.7%) 0.529 10/201 (5.0%) 8/204 (3.9%) 0.608
BSR (mm/1 h) < 5, >11 134/203 (66.0%) 124/202 (61.4%) 0.343 106/179 (59.2%) 114/187 (61.0%) 0.756
BSR (mm/2 h) > 25 82/202 (40.6%) 88/200 (44.0%) 0.470 44/178 (24.7%) 57/186 (30.6%) 0.207
BSR-blood sedimentation rate.
*comparison of nitroxoline vs. controls, logistic regression with random center effect.
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treated with nitroxoline and 7.8% with the control drugs.
Combining the vast clinical experience obtained from stud-
ies published earlier and non-inferiority of bacteriological
efficacy with nitroxoline versus the controls as documented
by this high quality IPD meta-analysis and considering the
world wide increase of resistance of uropathogens against
cotrimoxazole and fluoroquinolones, which has not been
seen with nitroxoline despite clinical usage for more than
20 years, nitroxoline should be reconsidered as one of the
first line antibiotics for the treatment of uncomplicated
UTI.
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